Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Operating Expenses (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Operating Expenses data on record, last reported at $12.3 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 4.51% year-over-year to $12.3 million; the TTM value through Dec 2025 reached $47.8 million, down 35.0%, while the annual FY2025 figure was $47.8 million, 35.0% down from the prior year.
  • Operating Expenses reached $12.3 million in Q4 2025 per VRCA's latest filing, down from $12.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $26.8 million in Q3 2023 and bottomed at $6.3 million in Q4 2022.
  • Average Operating Expenses over 5 years is $13.3 million, with a median of $11.8 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: soared 300.02% in 2023, then crashed 53.22% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $8.5 million in 2021, then decreased by 25.84% to $6.3 million in 2022, then skyrocketed by 300.02% to $25.1 million in 2023, then plummeted by 53.22% to $11.8 million in 2024, then rose by 4.51% to $12.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $12.3 million in Q4 2025, $12.7 million in Q3 2025, and $11.2 million in Q2 2025.